Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.69 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.69 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.60 |
| ▸ | CES1 | P23141 | 8/20 | 0.59 |
| ▸ | BCHE | P06276 | 4/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | APAF1 | O14727 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950200 | 1.00 | ALDH1A1 (0.69) | ALDH1A1ALDH3A1RCE1ALDH2CES1 | |
| SCHEMBL953499 | 0.86 | ALDH1A1 (0.60) | ALDH1A1ALDH3A1RCE1ALDH2CES1 | |
| SCHEMBL953500 | 0.86 | ALDH1A1 (0.60) | ALDH1A1ALDH3A1RCE1ALDH2CES1 | |
| SCHEMBL16798772 | 0.82 | ALDH1A1 (1.00) | ALDH1A1ALDH3A1RCE1ALDH2CES1 | |
| SCHEMBL16798771 | 0.82 | ALDH1A1 (1.00) | ALDH1A1ALDH3A1RCE1ALDH2CES1 | |
| SCHEMBL3949287 | 0.79 | CHRM5 (0.57) | ALDH1A1ALDH2CHRM5 | |
| SCHEMBL3949285 | 0.79 | CHRM5 (0.57) | ALDH1A1ALDH2CHRM5 | |
| SCHEMBL16798812 | 0.75 | ALDH1A1 (1.00) | ALDH1A1ALDH3A1RCE1ALDH2CES1 | |
| SCHEMBL16798810 | 0.75 | ALDH1A1 (1.00) | ALDH1A1ALDH3A1RCE1ALDH2CES1 | |
| SCHEMBL5426477 | 0.74 | ALDH1A1 (1.00) | ALDH1A1ALDH3A1ALDH2CES1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| EP-2013216-A2 | NOVEL SPIRO [IMIDAZOLIDINE-4, 3' -INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007091948-A2 | NOVEL SPIRO [IMIDAZOLIDINE-4, 3´-INDOLE] 2, 2´,5´(1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | claimed |
| US-20070185179-A1 | New compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| US-7868181-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090137650-A1 | New Compounds | LEUNG CARMEN | 2009-05-28 | — | — | US | disclosed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-2013216-A2 | NOVEL SPIRO [IMIDAZOLIDINE-4, 3' -INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1984374-A1 | USE OF SPIRO Ý IMIDAZOLIDINE-4, 3'-INDOLE¨2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | AstraZeneca AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091946-A1 | USE OF SPIRO [ IMIDAZOLIDINE-4, 3'-INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091948-A2 | NOVEL SPIRO [IMIDAZOLIDINE-4, 3´-INDOLE] 2, 2´,5´(1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185179-A1 | New compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137650-A1 | New Compounds | CLIC1, AQP1, AVPR2 | ALDH1A1 1551/4885ALDH3A1 2412/4885RCE1 67/4885 |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | ALDH1A1 502/4885ALDH3A1 701/4885RCE1 1709/4885 |
| US-20070185179-A1 | New compounds | CLIC1, AQP1, AVPR2 | ALDH1A1 1551/4885ALDH3A1 2412/4885RCE1 67/4885 |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | ALDH1A1 550/4885ALDH3A1 905/4885RCE1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.